2377845-98-0
2377845-98-0
Chemical Structure
Nofazinlimab
Synonym(s): CS1003
- CAS No.: 2377845-98-0
- Formula:N/A
- Molecular Weight:(145.08 kDa)
IUPAC Name: ((2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(1H-indol-1-yl)-4-(phosphonooxy)tetrahydro-2H-pyran-2-yl)methyl 1H-pyrrole-2-carboxylate
SMILES: [Nofazinlimab]
Biological Activity: Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nofazinlimab | 98.83% | Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ren Z, et al. LBA52 Nofazinlimab combined with lenvatinib versus placebo plus lenvatinib as first-line therapy for unresectable or metastatic hepatocellular carcinoma: A phase III, randomized, double-blind, multiregional study (CS1003-305)[J]. Annals of Oncology, 2025, 36: S1710-S1711.
- [2]. Chen H, et al. Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies. BMC Endocr Disord. 2023;23(1):139. Published 2023 Jul 6. [Content Brief]
